In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Progyny’s current price at $36.18 is below its PERT-weighted fair value of $69.92, signaling potential undervaluation, though Monte Carlo analysis shows high downside risk (94.4%) and volatility. Valuation methods diverge sharply, notably with strong P/E and EV/EBITDA valuations versus conservative DCF figures. Financial health scores reflect solid liquidity and leverage but moderate profitability and growth, implying balanced operational stability amid valuation uncertainty.